Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma

在自体干细胞移植（ASCT）后，采用卡非佐米、来那度胺和地塞米松（KRd）方案进行巩固治疗，可使新诊断的多发性骨髓瘤患者的微小残留病灶（MRD）阴性率显著升高，并在不使用双膦酸盐的情况下改善骨代谢。